FORWARD LOOKING STATEMENT

Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2022, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott is reimagining innovation for a better, healthier world

CREATING LIFE-CHANGING TECHNOLOGIES THAT ARE BOTH ACCESSIBLE AND AFFORDABLE

HELPING MORE PEOPLE IN MORE PLACES LIVE HEALTHIER AND FULLER LIVES

CREATING A HEALTHIER, MORE SUSTAINABLE WORLD AND COMPANY

Our goal is to help improve the lives of one in every three people on the planet by 2030
Abbott at a glance

115,000 PEOPLE
136 YEARS IN BUSINESS
160+ COUNTRIES
$43.7B 2022 SALES

TRUSTED PRODUCTS

Freestyle Libre
MicroClip
Similac
Alinity
Ensure
PediaSure
Duphaston
BinaxNOW
Pedialyte
Eterna
Scs System
AxENT
Simsulation
Xience
BRUFEN
AVEIR VR
Leadless Pacemaker

Products may not be available in all markets.
Abbott has a proven framework for achieving sustainable long-term growth and value creation.
Building strong momentum

Quarterly Sales *
(in billions)

* Excludes COVID-19 testing-related sales
Attractive pipeline to sustain top tier growth

**CURRENT GROWTH CONTRIBUTORS**
- FreeStyle Libre 3® Continuous Glucose Monitor
- Alinity® Suite of Diagnostics Systems/Automation
- MitraClip™ Transcatheter Mitral Valve Repair
- TriClip™ Transcatheter Tricuspid Valve Repair
- Aveir™ Leadless Pacemaker
- Navitor™ Transcatheter Aortic Valve Replacement
- Amulet™ Left Atrial Appendage Closure
- CardioMEMS™ Heart Failure Remote Monitoring System

**FUTURE GROWTH CONTRIBUTORS**
- Lingo™ Consumer biowearable sensors
- TBI Test Point of Care Traumatic Brain Injury Test
- FreeStyle Libre® Glucose + Ketone Sensor
- Esprit™ Below-The-Knee (BTK) Resorbable Stent
- Volt™ Pulsed Field Ablation (PFA) System
- Protality™ Nutritional Drink (preserves muscle during weight loss)
- Alinity n™ Next Generation Diagnostics System
- Biosimilars Portfolio of Biosimilars for Emerging Markets
Well-balanced capital allocation delivers strong shareholder returns

- Returning cash to shareholders
  - $17Bn returned in the form of dividends and share repurchases since 2021

- Investing for future growth
  - $5Bn in capital expenditures since 2021 to support future growth

- Built a fortress balance sheet
The Promise of AI in Healthcare

Uses of AI in Healthcare:
• For Diagnosis
• For Treatment
• To Empower Consumers

Abbott is leading the way:
• Technologies that predict cardiac events
• Data and Insights that improve treatment decisions and positively influence lifestyle choices
• Software tools that optimize procedure outcomes